Highlights in Mantle Cell Lymphoma From ASH 2020

Amanda F. Cashen, MD


December 29, 2020

Key studies were presented at the 2020 American Society of Hematology meeting on mantle cell lymphoma (MCL), including data on molecular subtyping, chemotherapy-free frontline treatment options, and new therapies including CAR T cells.

Dr Amanda Cashen of Washington University School of Medicine in St Louis, Missouri, reviews a whole-genome sequencing study of samples from patients with MCL that defined four MCL subgroups with distinct clinical outcomes.

She discusses multiple reports of chemotherapy-free frontline combination treatments with rituximab. One study reported long-term follow-up data on treatment with rituximab and lenalidomide that showed progression-free survival of approximately 60%. Results from a study of rituximab plus ibrutinib showed a response rate of 90%, though an increase of atrial fibrillation contributed to a 54% discontinuation rate.

Other presentations she reviews include a phase 1/2 study of LOXO-305, a next-generation oral BTK inhibitor with a favorable safety profile, and several studies showing the promise of anti-CD19 CAR T-cell therapies for the treatment of MCL.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.